LEO Pharma to Acquire Worldwide Rights to Dersimelagon From Tanabe Pharma
August 18, 2026
LEO Pharma entered into an agreement to acquire worldwide rights to dersimelagon from Tanabe Pharma. The oral, once-daily MC1R agonist is in development for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), with LEO Pharma expecting pre-launch investments in 2026 and a potential launch in 2027. The deal includes up to USD 435 million in upfront and near-term milestone payments plus potential downstream milestones and tiered royalties.
- Buyers
- LEO Pharma
- Targets
- Dersimelagon (worldwide rights)
- Sellers
- Tanabe Pharma
- Industry
- Pharmaceuticals
- Location
- Denmark
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.